Fatty liver disease (MASLD/MASH): trials for referral
424 open trials in the registries we read. Each row links to its registry record.
Registry data only. Frontlight does not judge whether a patient can take part: the trial team decides.
Where the open trials are
Type a city to sort by distance. The distance is worked out in your browser; the city is not sent anywhere.
400 trials shown · Showing the 400 most recently updated of 424 open trials.
Phase 269 sites
RecruitingUnited States
NCT07288138
A Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and in Combination, in Adults With Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH)
Eccogene
Registry updated 9 Nov 2026
Registry record: ClinicalTrials.govPhase 241 sites
RecruitingSpain, United Kingdom, Italy, Puerto Rico, United States
NCT07631637
Study to Evaluate ALN-CIDEB in Adults With Fibrotic Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Regeneron Pharmaceuticals
Registry updated 9 Nov 2026
Registry record: ClinicalTrials.govNo phase1 site
RecruitingIndia
NCT07391267
Pathogenesis of Chronic Kidney Disease Associated With Metabolic Dysfunction- Associated Fatty Liver Disease (MAFLD) and Treatment Response of Oral Semaglutide.
Institute of Liver and Biliary Sciences, India
Registry updated 9 Nov 2026
Registry record: ClinicalTrials.govPhase 3284 sites
RecruitingArgentina, Australia, Canada, Switzerland, Germany, Spain
NCT06215716
A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis
Akero Therapeutics, Inc
Registry updated 6 Nov 2026
Registry record: ClinicalTrials.govPhase 112 sites
RecruitingAustralia
NCT05945537
A Study of INI-822 in Healthy Volunteers and Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH) or Presumed MASH
Inipharm Australia Pty Ltd
Registry updated 6 Nov 2026
Registry record: ClinicalTrials.govNo phase0 sites
Not yet recruiting
NCT07922720
Efficacy of Carnitine Complex in Improving Hepatic Steatosis in Potential Liver Donors
Samsung Medical Center
Registry updated 6 Nov 2026
Registry record: ClinicalTrials.govPhase 327 sites
RecruitingJapan, United States
NCT07701993
A Pivotal Clinical Study to Investigate the Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)
GlaxoSmithKline
Registry updated 5 Nov 2026
Registry record: ClinicalTrials.govPhase 15 sites
RecruitingUnited States
NCT07358546
A Study of Efimosfermin Alfa in Adults With Hepatic Impairment
GlaxoSmithKline
Registry updated 5 Nov 2026
Registry record: ClinicalTrials.govPhase 224 sites
RecruitingUnited States
NCT06920043
A Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to MASH
GlaxoSmithKline
Registry updated 5 Nov 2026
Registry record: ClinicalTrials.govPhase 34 sites
RecruitingUnited States
NCT07854782
Trial to Evaluate ALN-CIDEB in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Regeneron Pharmaceuticals
Registry updated 5 Nov 2026
Registry record: ClinicalTrials.govPhase 332 sites
RecruitingJapan, United States
NCT07704892
A Study to Investigate Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)
GlaxoSmithKline
Registry updated 5 Nov 2026
Registry record: ClinicalTrials.govPhase 21 site
RecruitingChina
NCT07145151
A Study of UBT251 in Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH)
The United Bio-Technology (Hengqin) Co., Ltd.
Registry updated 3 Nov 2026
Registry record: ClinicalTrials.govPhase 334 sites
Not yet recruitingChina, Germany, Spain, United Kingdom, United States
NCT07850063
ELEVATE-LIVER: A Study to Test Whether Survodutide Helps Improve Heart Structure and Function in People With Overweight or Obesity and Fatty Liver Disease
Boehringer Ingelheim
Registry updated 30 Oct 2026
Registry record: ClinicalTrials.govPhase 21 site
Not yet recruitingIndia
NCT07902219
Qurse Revand for MASLD: A Randomized Controlled Safety and Efficacy Trial
National Institute of Unani Medicine, Bengaluru
Registry updated 28 Oct 2026
Registry record: ClinicalTrials.govPhase 2/31 site
Not yet recruitingEgypt
NCT07900087
Evaluating the Safety and Efficacy of Roflumilast in the Treatment of Nonalcoholic Fatty Liver Disease Patients
Tanta University
Registry updated 28 Oct 2026
Registry record: ClinicalTrials.govPhase 3454 sites
RecruitingArgentina, Austria, Australia, Belgium, Bulgaria, Brazil
NCT06632457
LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis
Boehringer Ingelheim
Registry updated 28 Oct 2026
Registry record: ClinicalTrials.govPhase 2/31 site
Not yet recruitingEgypt
NCT07900100
Evaluating the Safety and Efficacy of Rupatadine in the Treatment of Nonalcoholic Fatty Liver Disease Patients.
Tanta University
Registry updated 28 Oct 2026
Registry record: ClinicalTrials.govPhase 3536 sites
RecruitingArgentina, Austria, Australia, Belgium, Bulgaria, Brazil
NCT06632444
LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis
Boehringer Ingelheim
Registry updated 28 Oct 2026
Registry record: ClinicalTrials.govPhase 21 site
RecruitingUnited States
NCT03884075
Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Registry updated 27 Oct 2026
Registry record: ClinicalTrials.govPhase 41 site
Not yet recruitingEgypt
NCT07891234
Effect of SGLT2 Inhibitor on Metabolic-Dysfunction-Associated Fatty Liver Disease in Patients With Insulin Resistance
Sherihan AboElyazed Mohamed Khalil
Registry updated 23 Oct 2026
Registry record: ClinicalTrials.govPhase 3316 sites
RecruitingArgentina, Austria, Australia, Belgium, Bulgaria, Canada
NCT06318169
A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
Hoffmann-La Roche
Registry updated 23 Oct 2026
Registry record: ClinicalTrials.govPhase 3277 sites
RecruitingArgentina, Australia, Belgium, Bulgaria, Brazil, Canada
NCT06419374
A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
Hoffmann-La Roche
Registry updated 23 Oct 2026
Registry record: ClinicalTrials.govPhase 41 site
RecruitingUnited States
NCT07058155
Optimizing Portal Hypertension With TIPS and Interval Metabolic Surgery for Advanced Liver Disease
The Cleveland Clinic
Registry updated 22 Oct 2026
Registry record: ClinicalTrials.govPhase 20 sites
Not yet recruiting
NCT07620366
To Evaluate the Efficacy and Safety of QL2401 in Patients With Metabolic Dysfunction-associated Steatohepatitis and Liver Fibrosis
Qilu Pharmaceutical Co., Ltd.
Registry updated 22 Oct 2026
Registry record: ClinicalTrials.govPhase 416 sites
RecruitingUnited States
NCT07848191
Rezdiffra® With Concomitant Therapies Commonly Used to Treat Comorbidities in Adults With MASH and F2-F3 Fibrosis
Madrigal Pharmaceuticals, Inc.
Registry updated 16 Oct 2026
Registry record: ClinicalTrials.govPhase 21 site
Not yet recruitingChina
NCT07878091
A Phase 2a Study of Kylo-0603 Capsule in Participants With Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD)
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
Registry updated 16 Oct 2026
Registry record: ClinicalTrials.govPhase 15 sites
RecruitingUnited States
NCT07830758
Resmetirom in Patients With MASH and HFpEF
Madrigal Pharmaceuticals, Inc.
Registry updated 16 Oct 2026
Registry record: ClinicalTrials.govPhase 227 sites
RecruitingCanada, United States
NCT07325526
A Study to Test Whether BI 3802876 is Tolerated in People With Compensated Liver Cirrhosis Due to Metabolic Dysfunction- Associated Steatohepatitis (MASH)
Boehringer Ingelheim
Registry updated 14 Oct 2026
Registry record: ClinicalTrials.govPhase 3282 sites
RecruitingArgentina, Australia, Brazil, Canada, Switzerland, Chile
NCT06528314
A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
Akero Therapeutics, Inc
Registry updated 13 Oct 2026
Registry record: ClinicalTrials.govPhase 31 site
Not yet recruitingEgypt
NCT07863648
Vitamin E Versus Silymarin in Non Diabetic MASLD Patients
Kafrelsheikh University
Registry updated 13 Oct 2026
Registry record: ClinicalTrials.gov
The same sites as a list
- United States101 open trials
- China66 open trials
- France30 open trials
- Spain29 open trials
- Italy27 open trials
- United Kingdom21 open trials
- Egypt21 open trials
- Germany20 open trials
- India18 open trials
- Canada17 open trials
- Taiwan15 open trials
- South Korea14 open trials
- Belgium14 open trials
- Poland13 open trials
- Türkiye11 open trials
- Australia10 open trials
- Netherlands10 open trials
- Japan9 open trials
- Hong Kong9 open trials
- Puerto Rico8 open trials
- Czechia8 open trials
- Mexico8 open trials
- Bulgaria7 open trials
- Switzerland7 open trials
- Argentina6 open trials
- Singapore6 open trials
- Austria6 open trials
- Denmark6 open trials
- Brazil5 open trials
- New Zealand5 open trials
- Romania5 open trials
- Greece5 open trials
- Israel4 open trials
- Chile4 open trials
- Saudi Arabia4 open trials
- Finland4 open trials
- Pakistan4 open trials
- Hungary3 open trials
- Sweden3 open trials
- Thailand3 open trials
- South Africa2 open trials
- Georgia2 open trials
- Kuwait2 open trials
- Vietnam1 open trial
- Ireland1 open trial
- Russia1 open trial
- Kazakhstan1 open trial
- Norway1 open trial
- Iran1 open trial
- Malaysia1 open trial
- Guadeloupe1 open trial
- Réunion1 open trial
- French Guiana1 open trial
- Cyprus1 open trial
- Croatia1 open trial
- Indonesia1 open trial
- Portugal1 open trial
Who treats this
Institutions with trials or publications in this disease (OpenAlex, registries). Institutions only, no people.
First Affiliated Hospital of Wenzhou Medical University
Wenzhou, China
8 trials · 87 publications · ROR
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
Milan, Italy
25 trials · 49 publications · ROR
What changed in the last 7 days
Registry facts, one per line, newest first.
Status changed: Running, not recruiting → Completed
Essentiale® liquid once-daily Phase III study
2025-521678-32-00 · Phase 3 · Bulgaria, Germany, Poland
Source: EU CTISNew in the registry
Efficacy of Carnitine Complex in Improving Hepatic Steatosis in Potential Liver Donors
NCT07922720 · No phase
Source: ClinicalTrials.govNew in the registry
Periodontal Status and Biomarkers in MASLD
NCT07923409 · No phase
Source: ClinicalTrials.govClosed for recruitment
Screening for Hyperuricemia in Patients With Metabolic Associated Fatty Liver Disease (MAFLD)
NCT07053709 · No phase · Egypt
Source: ClinicalTrials.govClosed for recruitment
Detection of Helicopacter Pylori in Patients With Metabolic Associated Fatty Liver Disease
NCT07128147 · No phase · Egypt
Source: ClinicalTrials.govClosed for recruitment
Efficacy of Essential Phospholipid Versus Betaine HCL/L-Glutamic Acid in MAFLD
NCT07194863 · No phase · Egypt
Source: ClinicalTrials.govClosed for recruitment
Prevalence of Obesity in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
NCT07451366 · No phase · Egypt
Source: ClinicalTrials.govOpened for recruitment
NCT07631637 · Phase 2 · Spain, United Kingdom, Italy, Puerto Rico, United States
Source: ClinicalTrials.govStatus changed: Recruiting → By invitation only
NCT06845345 · Phase 4 · Netherlands
Source: ClinicalTrials.govOpened for recruitment
Reducing Non-Alcoholic Steatohepatitis
NCT06519448 · Phase 4 · Czechia
Source: ClinicalTrials.govStatus changed: Completed → Running, not recruiting
NCT06151964 · Phase 1/2 · Austria, Canada, Germany, Japan, Sweden
Source: ClinicalTrials.govStatus changed: Completed → Running, not recruiting
Phase 2b Study of GSK4532990 in Adults With NASH
NCT05583344 · Phase 2 · Argentina, Australia, Belgium, Canada, Spain, France
Source: ClinicalTrials.govStatus changed: By invitation only → Not yet recruiting
Reducing Non-Alcoholic Steatohepatitis
NCT06519448 · Phase 4 · Czechia
Source: ClinicalTrials.govStatus changed: Recruiting → Not yet recruiting
NCT07631637 · Phase 2 · Spain, United Kingdom, Italy, Puerto Rico, United States
Source: ClinicalTrials.govClosed for recruitment
Target of Suv420h1/2 in Hepatocytes
NCT06332677 · No phase · Italy
Source: ClinicalTrials.govClosed for recruitment
DEFINITION OF THE GENOMIC LANDSCAPE OF MASLD
NCT07249112 · No phase · Italy
Source: ClinicalTrials.govNew in the registry
Personalized Dietary Feedback to Reduce Hepatic Steatosis in Patients With MASLD
NCT07914829 · No phase · Austria
Source: ClinicalTrials.govClosed for recruitment
NCT06836609 · Phase 1/2 · United Kingdom, United States
Source: ClinicalTrials.gov
Show more
Phase changed: No phase → Phase 4
Reducing Non-Alcoholic Steatohepatitis
NCT06519448 · Phase 4 · Czechia
Source: ClinicalTrials.gov
Results card
Trials that finished or stopped in the last 3 years, with the reason the registry gives and linked publications.
Phase 3Ended 6 Nov 2026
Phase 1Ended 30 Oct 2026
Completed124 participants
2024-513549-36-01
A study to test how well different doses of BI 3804379 are tolerated by healthy people and patients with MASH
No phaseEnded 18 Oct 2026
No phaseEnded 1 Oct 2026
Completed200 participants
NCT07128147
Detection of Helicopacter Pylori in Patients With Metabolic Associated Fatty Liver Disease
No phaseEnded 1 Oct 2026
Completed200 participants
NCT07194863
Efficacy of Essential Phospholipid Versus Betaine HCL/L-Glutamic Acid in MAFLD
Phase 1Ended 22 Sept 2026
Phase 1Ended 15 Sept 2026
No phaseEnded 15 Sept 2026
Completed146 participants
NCT07881796
Effect of Dapagliflozin on Metabolic Parameters in Patients With Non-Alcoholic Fatty Liver Disease
No phaseEnded 31 Aug 2026
Phase 2Ended 24 Aug 2026
Completed175 participants
NCT06108219
A Phase 2b, Study Evaluating Miricorilant in Adult Patients With Nonalcoholic Steatohepatitis/Metabolic Dysfunction-Associated Steatohepatitis (MONARCH)
- Phase 1b study of miricorilant in patients with presumed metabolic dysfunction-associated steatohepatitis (MASH). · Hepatology (Baltimore, Md.), 2026
No phaseEnded 15 Aug 2026
Phase 3Ended 10 Aug 2026
Completed31 participants
NCT05935826
Effect of Amino Acids on Hepatic Fat Content in Adolescents (AMINOS Study)
No phaseEnded 8 Aug 2026
Completed220 participants
NCT06682663
Impact of Live Streaming Exercise on Liver Health in MASLD Pregnant Women
No phaseEnded 7 Aug 2026
No phaseEnded 5 Aug 2026
Completed16 participants
NCT07073326
Effects of Normobaric Hypoxic Training in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Phase 2Ended 3 Aug 2026
Completed85 participants
NCT06465186
A Clinical Study of Efinopegdutide in People With Compensated Cirrhosis Due to Steatohepatitis (MK-6024-017)
No phaseEnded 31 Jul 2026
Completed565 participants
NCT06720766
Assessment of FibbroScan in Diagnosing MASLD Among the Chinese Population With Obesity
No phaseEnded 31 Jul 2026
Completed861 participants
NCT05351515
Prevalence of Non-alcoholic Fatty Liver Disease Among Non-obese Obstructive Sleep Apnea by Using Transient Elastography
No phaseEnded 21 Jul 2026
Completed50 participants
NCT05268042
Moderately Carbohydrate-restricted Diet to Treat NAFLD in Adolescents
Phase 4Ended 16 Jul 2026
Completed72 participants
NCT05493761
Effect of Anti-osteoporotic Medications on Nonalcoholic Fatty Liver Disease
Show more
Phase 2Ended 15 Jul 2026
Completed215 participants
NCT04505436
Efocipegtrutide (HM15211) in Adults With Biopsy-Confirmed Nonalcoholic Steatohepatitis (NASH)
No phaseEnded 9 Jul 2026
Withdrawn before start0 participants
NCT04302051
Assessment of Fatty Liver With Thermo-acoustic Device
Reason given: The sponsor withdrew from the study
No phaseEnded 9 Jul 2026
Withdrawn before start0 participants
NCT06982378
GLP-1 RA on Liver OMICS in MASLD
Reason given: no grant approved
No phaseEnded 1 Jul 2026
Completed200 participants
NCT07451366
Prevalence of Obesity in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
No phaseEnded 1 Jul 2026
Completed271 participants
NCT07791589
Fibrosis and Metabolic Markers in Relation to PREVENT Cardiovascular Risk in MASLD
No phaseEnded 30 Jun 2026
No phaseEnded 15 Jun 2026
Completed45 participants
NCT07294963
Impact of Lifestyle Interventions on Cognitive Decline in Non-alcoholic Fatty Liver Disease
No phaseEnded 15 Jun 2026
Completed100 participants
NCT07663682
Correlation Between Serum Nociceptin and Sympathetic Nerve Activity in Diabetic Patients With MAFLD
Phase 2Ended 3 Jun 2026
Completed228 participants
NCT05327127
Study to Evaluate the Efficacy and Safety of K-877-ER and CSG452 in Participants With NASH With Liver Fibrosis
No phaseEnded 3 Jun 2026
Stopped early30 participants
NCT03587831
Vertical Sleeve Gastrectomy and Lifestyle Modification for the Treatment of Non-Alcoholic Steatohepatitis
Reason given: Study has been terminated due to poor recruitment and early evidence of futility
No phaseEnded 31 May 2026
Completed1000 participants
NCT07730736
Analysis of Clinical Characteristics of Chronic Hepatitis B Combined With MAFLD in Different TCM Syndrome Types
No phaseEnded May 2026
No phaseEnded 15 May 2026
Phase 1Ended 12 May 2026
Completed115 participants
NCT05395481
A Single-Ascending and Repeated Dose Study of LY3849891 in Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Phase 2Ended 21 Apr 2026
Completed67 participants
NCT06410924
A Study to Evaluate DD01 in Overweight/Obese Subjects With MASLD/MASH
No phaseEnded 8 Apr 2026
Completed36 participants
NCT06275906
Influence of a Mediterranean Diet Combined With a Physical Activity Intervention, on NAFLD and Inflammation Parameters.
Phase 3Ended 3 Apr 2026
Completed150 participants
NCT06117137
The Impact Of SGLT2 -I on Metabolic Dysfunction -Associated Steatotic Liver Disease In Patients With Type 2 Diabetes Mellitus
No phaseEnded 1 Apr 2026
Phase 1/2Ended 31 Mar 2026
Phase 1Ended 31 Mar 2026
Withdrawn before start0 participants
NCT06126354
Dexamethasone/Pancreatic Clamp P&F
Reason given: Investigators' scientific priorities shifted.
No phaseEnded 31 Mar 2026
Stopped early103 participants
NCT05292352
Prevention of NAFLD in Hispanic Children
Reason given: Study was terminated due to a lack of funding. Data collection was completed for 12-month outcomes; however, funding limitations prevented follow-up for longer timeframes, and some outcomes were not fully collected.
No phaseEnded 26 Mar 2026
Withdrawn before start0 participants
NCT05827432
FCI Effectiveness in NAFLD Stratification
Reason given: Funding period ended.
No phaseEnded 15 Mar 2026
Completed1519 participants
NCT06493253
Digital Pathology and AI for Liver Outcomes in MASLD (DPAILO-2)
Phase 2Ended 13 Mar 2026
Stopped early10 participants
NCT06939816
Vonafexor in Patients With Impaired Renal Function and Suspected MASH (Metabolic Dysfunction-associated Steatohepatitis)
Reason given: Pilot cohort (n=10) yielded useful insights but data remains exploratory due to limited sample size. Study stopped due to strategic reprioritization.
No phaseEnded 1 Mar 2026
Completed17 participants
NCT06195943
Feasibility, Safety and Acceptability of a Mobile Health Delivered Exercise Training Program in Patients With Nonalcoholic Steatohepatitis
No phaseEnded 28 Feb 2026
Completed135 participants
NCT04591106
Quantifying Body Composition and Liver Disease in Children Using Free-Breathing MRI and MRE
No phaseEnded 27 Feb 2026
Phase 1/2Ended 26 Feb 2026
Completed30 participants
NCT05506488
Dasatinib and Quercetin to Treat Fibrotic Non-alcoholic Fatty Liver Disease
Phase 4Ended 26 Feb 2026
Completed24 participants
2023-506300-12-00
Effects of extensive Weight loss on Insulin resistance and Lipid-kinetics in people with obesity and fatty liver Disease
No phaseEnded 20 Feb 2026
Completed75 participants
NCT07622680
Comparative Effects of Mediterranean and DASH Diet on Hepatic Function
No phaseEnded 19 Feb 2026
Completed63 participants
NCT06392828
EndoNAFLD: Relationship Between Fatty Liver Disease and Cardiovascular Diseases
No phaseEnded 10 Feb 2026
No phaseEnded 5 Feb 2026
No phaseEnded 22 Jan 2026
Completed110 participants
NCT05930093
Evaluate the Efficacy and Safety of LivPhcD Capsules in the NAFLD Subjects
No phaseEnded 20 Jan 2026
Completed80 participants
NCT06389851
Effects of Tomato Consumption on Steatosis, Intestinal Function and Glucose and Lipid Metabolism in Subjects With NAFLD
No phaseEnded 17 Jan 2026
No phaseEnded 14 Jan 2026
Completed50 participants
NCT07200934
Effect of Adding TENS to Mediterranean Diet on Appetite and Liver Enzymes in Nonalcoholic Fatty Liver Patients
Phase 2Ended 13 Jan 2026
Completed28 participants
NCT06675929
A Study to Test How Well BI 770371 is Tolerated by People With Cirrhosis Caused by a Liver Disease Called MASH
No phaseEnded 1 Jan 2026
Completed269901 participants
NCT07816211
External Transportability Validation, Implementation Readiness, and Outcome Association of the TransHepMet-Mort Liver Metabolic Mortality Risk Model
No phaseEnded 31 Dec 2025
Completed300 participants
NCT07730905
Analysis of Renal Impairment Characteristics and High-Risk Factors in Chronic Hepatitis B Patients on Long-Term Oral Nucleos(t)Ide Analogues
Not medical advice. fetched 10 Nov 2026